These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 12766382

  • 1. Cardiovascular therapy in patients with renal insufficiency.
    Ruilope LM, Segura J.
    Cardiovasc Drugs Ther; 2002 Dec; 16(6):497-501. PubMed ID: 12766382
    [Abstract] [Full Text] [Related]

  • 2. The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue?
    Ruilope LM, Campo C, Segura J.
    Curr Hypertens Rep; 2001 Oct; 3(5):419-21. PubMed ID: 11551377
    [Abstract] [Full Text] [Related]

  • 3. What is the optimal blood pressure target in renal patients?
    Ruilope LM, Campo C, Segura J, Rodicio JL.
    Adv Nephrol Necker Hosp; 2001 Oct; 31():43-53. PubMed ID: 11692470
    [Abstract] [Full Text] [Related]

  • 4. Treatment of renal failure and blood pressure.
    Silverman M, Bakris GL.
    Curr Opin Nephrol Hypertens; 1997 May; 6(3):237-42. PubMed ID: 9263666
    [Abstract] [Full Text] [Related]

  • 5. Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
    García de Vinuesa S, Luño J, Gómez-Campderá F, Ridao N, Sánchez M, Dall'Anese C, Valderrábano F.
    Nephrol Dial Transplant; 2001 May; 16 Suppl 1():78-81. PubMed ID: 11369828
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
    Ritz E, Orth SR, Strzelczyk P.
    J Hypertens Suppl; 1997 Mar; 15(2):S21-6. PubMed ID: 9218194
    [Abstract] [Full Text] [Related]

  • 7. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR.
    Drugs; 2005 Mar; 65 Suppl 2():29-39. PubMed ID: 16398060
    [Abstract] [Full Text] [Related]

  • 8. Treatment of hypertension in chronic kidney disease.
    Toto RD.
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [Abstract] [Full Text] [Related]

  • 9. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection.
    Locatelli F, Del Vecchio L, Andrulli S, Colzani S.
    Kidney Int Suppl; 2002 Dec; (82):S53-60. PubMed ID: 12410856
    [Abstract] [Full Text] [Related]

  • 10. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A, Peeters P, Vanholder R.
    Acta Clin Belg; 2004 Dec; 59(1):44-56. PubMed ID: 15065696
    [Abstract] [Full Text] [Related]

  • 11. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A.
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R, Tonolo G.
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [Abstract] [Full Text] [Related]

  • 13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 14. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial.
    PROCOPA Study Group.
    J Hypertens; 2002 Apr; 20(4):729-37. PubMed ID: 11910310
    [Abstract] [Full Text] [Related]

  • 15. Endothelial function and the kidney. An emerging target for cardiovascular therapy.
    Rabelink TJ, Koomans HA.
    Drugs; 1997 Apr; 53 Suppl 1():11-9. PubMed ID: 9034751
    [Abstract] [Full Text] [Related]

  • 16. Renal function: the Cinderella of cardiovascular risk profile.
    Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF.
    J Am Coll Cardiol; 2001 Dec; 38(7):1782-7. PubMed ID: 11738274
    [Abstract] [Full Text] [Related]

  • 17. Audit of antihypertensive treatment in patients with renal failure.
    Schwenger V, Ritz E.
    Nephrol Dial Transplant; 1998 Dec; 13(12):3091-5. PubMed ID: 9870471
    [Abstract] [Full Text] [Related]

  • 18. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [Abstract] [Full Text] [Related]

  • 19. A Systematic Review on the Efficacy of Amlodipine in the Treatment of Patients With Hypertension With Concomitant Diabetes Mellitus and/or Renal Dysfunction, When Compared With Other Classes of Antihypertensive Medication.
    Jeffers BW, Robbins J, Bhambri R, Wajsbrot D.
    Am J Ther; 2015 Dec; 22(5):322-41. PubMed ID: 25738570
    [Abstract] [Full Text] [Related]

  • 20. Renal protection and antihypertensive drugs: current status.
    Salvetti A, Mattei P, Sudano I.
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.